Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS.
Tseng JE, et al. Among authors: myers jn.
Cancer. 2001 Nov 1;92(9):2364-73. doi: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p.
Cancer. 2001.
PMID: 11745292
Clinical Trial.